Cantor Fitzgerald CEO Lutnick vies for US Treasury secretary post
According to reports, Cantor Fitzgerald CEO Howard Lutnick is now in the running to become President-elect Trump's Treasury ...
Amgen Dismisses Bone Density Concerns Related to Its New Weight-Loss Drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
bovnews16h
Cantor Fitzgerald Just Upgraded Teradyne Inc (TER) Stock—What Does This Mean for Investors?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.73% of ...
Some of Trump's key cabinet picks provide clues to how his administration will approach the business world
President-elect Donald Trump's picks for US attorney general and secretary of state illustrate a potential hardline approach ...
Howard Lutnick making push for Treasury job, setting up battle with leading contender Bessent
Cantor Fitzgerald CEO and President-elect Donald Trump’s transition co-chair, Howard Lutnick, is said to be "campaigning hard ...
This is why small caps should perform well into the year-end - Cantor Fitzgerald
Small caps’ (NYSEARCA:IWM), (SP600) outperformance should continue into the year-end, according to Eric Johnston, senior ...
Crypto Industry Lobbies Trump and His Allies to Capitalize on Election Wins
As Bitcoin soars to record highs, cryptocurrency executives are maneuvering to influence Donald J. Trump’s transition and ...
STAT2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (NASDAQ:AMGN) shares fell in the evening hours on Tuesday after Cantor Fitzgerald argued that a potential loss of bone ...